pH-Responsive Nanoparticles for Delivery of Paclitaxel to the Injury Site for Inhibiting Vascular Restenosis
A high incidence of restenosis has been reported at the site of inflammation following angioplasty and stent implantation. The anti-proliferative drug paclitaxel (PTX) could help to reduce inflammation and restenosis; however, it has poor water solubility and serious adverse side effects at high dos...
Main Authors: | Huiru Zhu, Li Kong, Xu Zhu, Tingting Ran, Xiaojuan Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/3/535 |
Similar Items
-
Vascular restenosis following paclitaxel-coated balloon therapy is attributable to NLRP3 activation and LIN9 upregulation
by: Qinghui Kan, et al.
Published: (2024-09-01) -
Safety and efficacy of the Essential Pro paclitaxel drug-eluting balloon for the treatment of coronary in-stent restenosis
by: Lucio Padilla, et al.
Published: (2024-08-01) -
Nanoparticle-based approaches for treating restenosis after vascular injury
by: Liangfeng Zhao, et al.
Published: (2024-10-01) -
Paclitaxel-Coated versus Uncoated Balloon for Femoropopliteal In-Stent Restenosis: A Systematic Review and Meta-Analysis
by: Qiwei Li, et al.
Published: (2022-09-01) -
Glycosylation-Engineered Platelet Membrane-Coated Interleukin 10 Nanoparticles for Targeted Inhibition of Vascular Restenosis
by: Li F, et al.
Published: (2023-09-01)